Aclaris Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed February 25, 2020. The filing is an annual report, not a quarterly Form 10-Q. Aclaris is a physician-led biopharmaceutical company focused on immuno-inflammatory diseases.
Business Context and Strategic Position
- Following a September 2019 strategic review, Aclaris refocused resources on immuno-inflammatory development programs and began pursuing partners for its drug candidates and ESKATA.
- Lead program ATI-450, an oral MK2 inhibitor, completed a Phase 1 trial in 77 healthy subjects. The company reported generally favorable tolerability and intended to begin a Phase 2a rheumatoid arthritis trial in the first half of 2020.
- A-101 45% Topical Solution completed two Phase 3 common-wart trials with statistically significant primary and secondary outcomes and no treatment-related serious adverse events reported. Aclaris was seeking a commercialization partner.
- ATI-1777, a topical soft-JAK inhibitor, was expected to enter an IND filing in mid-2020, with a potential Phase 1/2 trial in the second half of 2020. ATI-2138, an oral ITJ inhibitor, was expected to enter an IND filing in the fourth quarter of 2020 or first quarter of 2021.
- ESKATA, the company’s only FDA-approved product, was voluntarily withdrawn from U.S. commercialization in August 2019. Aclaris continued to maintain the U.S. NDA while seeking a strategic partner.
- RHOFADE rights were sold to EPI Health in October 2019. Aclaris retained potential sales milestones of up to $20.0 million, a high-single-digit royalty on specified net sales, and certain foreign licensing-related proceeds.
Financial Performance and Liquidity
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Total continuing-operations revenue | $4.2 million | $6.2 million | Down $1.9 million |
| Contract research revenue | $4.2 million | $4.7 million | Down $0.4 million |
| Research and development expense | $64.9 million | $60.8 million | Up $4.1 million |
| Loss from continuing operations | $113.5 million | $82.1 million | Loss increased $31.4 million |
| Loss from discontinued operations | $47.8 million | $50.6 million | Improved $2.8 million |
| Net loss | $161.4 million | $132.7 million | Loss increased $28.6 million |
| Net loss per share | $3.90 | $4.03 | Improved on a per-share basis |
| Net cash used in operating activities | $96.4 million | $100.8 million | Improved $4.4 million |
Continuing-operations revenue was almost entirely contract research revenue. Product sales were reclassified to discontinued operations for all periods. Including discontinued operations, 2019 product sales were $13.9 million, consisting of $13.6 million of RHOFADE sales and $0.3 million of ESKATA sales.
- Loss from operations was $111.1 million, compared with $84.8 million in 2018. The implied operating margin was deeply negative and is not economically meaningful for a development-stage company with minimal continuing revenue.
- Key 2019 expense items included $64.9 million of R&D, $27.2 million of general and administrative expense, $18.5 million of goodwill impairment, and $0.7 million of increased contingent consideration.
- Cash, cash equivalents and marketable securities totaled $75.0 million at December 31, 2019, including $35.9 million of cash, cash equivalents and restricted cash and $39.1 million of marketable securities.
- Total assets declined to $98.3 million from $275.6 million, primarily reflecting the RHOFADE disposition, impairment charges, and cash utilization. Stockholders’ equity declined to $69.9 million from $215.1 million.
- The $30.0 million Oxford term loan was repaid in full in October 2019. The company reported no long-term debt at year-end, although lease liabilities and contingent consideration remained.
- Investing activities provided $105.7 million, including $34.2 million of cash from the RHOFADE disposition and net proceeds from marketable-security activity. Financing activities used $30.3 million, principally for debt repayment.
Material Changes Versus the Prior Comparable Period
- R&D spending increased 6.7% to $64.9 million. ATI-450 spending increased to $8.2 million from $4.1 million, while A-101 spending increased to $13.3 million from $10.1 million. JAK-inhibitor spending declined to $15.2 million from $22.5 million as several Phase 2 trials concluded.
- Continuing revenue declined because 2018 included $1.5 million of Cipher licensing revenue; 2019 revenue consisted of contract research revenue of $4.2 million.
- Goodwill of $18.5 million was fully impaired in 2019 following a decline in the company’s stock price and the resulting valuation of the therapeutics reporting unit.
- A $27.6 million impairment charge was recorded on the RHOFADE intangible asset and reported in discontinued operations.
- RHOFADE was sold after less than a year of ownership, following the company’s decision to discontinue commercial operations and seek a partner.
- The company restructured operations and terminated 63 employees, with an additional 23 employees given transition notices. It recorded $2.7 million of termination-benefit expense and accrued potential retention bonuses.
- Other income shifted to net expense of $2.5 million from $2.7 million of income, primarily because of interest and related costs on the Oxford debt, which was subsequently repaid.
Outlook, Risks, Contingencies and Unusual Items
- Management expected continuing losses and negative operating cash flow while funding ATI-450, preclinical programs, and discovery efforts. Additional capital was expected to be required, although the company stated that year-end liquidity should fund operations and capital expenditures for more than 12 months under current assumptions.
- Management acknowledged that the funding assessment depends on development timing, spending control, partnering transactions, regulatory outcomes, and access to equity or debt financing. Failure to raise capital or secure partners could require material reductions or discontinuation of development programs.
- Remaining potential obligations include up to $76.0 million of Rigel development milestones, up to $10.5 million under an additional Rigel milestone set, $1.5 million of Rigel amendment fees payable in 2020, up to $75.0 million of Confluence contingent consideration, and milestone and royalty obligations under the Vixen and Columbia arrangements.
- The company relies on third parties for clinical research, manufacturing, supply, and distribution and has no manufacturing facilities. Supply interruptions, quality problems, regulatory findings, or contractor failures could delay development.
- Aclaris and certain officers and directors faced consolidated securities and derivative lawsuits relating primarily to alleged disclosures concerning ESKATA’s risks, tolerability, effectiveness, and advertising practices. The company disputed the claims and intended to defend them.
- EPI Health, after acquiring RHOFADE rights, was substituted as plaintiff in patent litigation against Taro concerning a proposed generic RHOFADE product. A successful generic challenge could reduce future royalties and milestone proceeds.
- Patent protection varies by program and jurisdiction. Certain ESKATA and A-101 use patents begin expiring in 2022, while ATI-450 patents generally extend to 2034; patents for ATI-1777 and ATI-2138 were primarily pending at year-end.
- Potential dilution, regulatory failure, clinical-trial failure, reimbursement constraints, competitive products, product liability, intellectual-property disputes, and volatility in the company’s stock price remain significant risks.
Investor Verification Checklist
- Verify the $75.0 million liquidity figure, including the $1.75 million of RHOFADE proceeds held in escrow, and reconcile it to the balance sheet and projected operating cash burn.
- Review the company’s cash runway assumptions and the timing and terms of any subsequent equity financing, debt financing, or partnering transaction.
- Confirm the status and results of the planned ATI-450 Phase 2a trial, the ATI-1777 IND, and the ATI-2138 development timeline.
- Assess whether A-101 45% has obtained a partner or advanced toward an NDA and commercialization.
- Monitor EPI Health’s RHOFADE sales, royalty and milestone performance and the outcome of the Taro patent litigation.
- Review the consolidated securities and derivative actions, including any settlements, motions, insurance coverage, or potential liabilities.
- Reconcile continuing versus discontinued operations when comparing revenue, expenses, margins, and product performance with prior filings.